enGene extends momentum with another 14% surge on Friday
Seeking Alpha News (Fri, 23-Jan 4:08 PM ET)
enGene Secures Expanded $125 Million Debt Facility to Advance Bladder Cancer Gene Therapy
TipRanks (Tue, 20-Jan 6:14 PM ET)
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
Business Wire (Tue, 20-Jan 5:35 PM ET)
Business Wire (Tue, 2-Dec 7:30 AM ET)
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
Business Wire (Tue, 25-Nov 7:30 AM ET)
enGene’s $130 Million Offering Highlights Investor Confidence in Genetic Medicine Platform
Market Chameleon (Thu, 13-Nov 3:25 AM ET)
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
Business Wire (Thu, 13-Nov 12:27 AM ET)
enGene Announces Proposed Public Offering of Common Shares
Business Wire (Wed, 12-Nov 4:01 PM ET)
Market Chameleon (Tue, 11-Nov 5:28 AM ET)
Market Chameleon (Tue, 11-Nov 4:09 AM ET)
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Engene Holdings trades on the NASDAQ stock market under the symbol ENGN.
As of January 23, 2026, ENGN stock price climbed to $12.17 with 1,823,279 million shares trading.
ENGN has a beta of 0.36, meaning it tends to be less sensitive to market movements. ENGN has a correlation of 0.01 to the broad based SPY ETF.
ENGN has a market cap of $815.20 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ENGN belongs to (by Net Assets): AVSC.
ENGN has outperformed the market in the last year with a price return of +66.9% while the SPY ETF gained +14.2%. ENGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +54.7% and +38.1%, respectively, while the SPY returned +2.9% and -0.7%, respectively.
ENGN support price is $10.09 and resistance is $11.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENGN shares will trade within this expected range on the day.
